Neurology Department, Hospital del Mar Medical Research Institute (IMIM), Barcelona.
Neurology Department, Universitat Autònoma de Barcelona, Hospital del Mar Medical Research Institute (IMIM), Barcelona.
Eur J Neurol. 2018 Jul;25(7):925-933. doi: 10.1111/ene.13622. Epub 2018 Apr 15.
Cytomegalovirus (CMV) infection has recently been associated with a lower multiple sclerosis (MS) susceptibility, although it remains controversial whether it has a protective role or is merely an epiphenomenon related to westernization and early-life viral infections. We aimed to evaluate whether CMV serostatus may differ in patients with early MS as compared with patients with non-early MS, analyzing the putative association of this virus with MS clinical course and humoral immune responses against other herpesviruses.
Multicentric analysis was undertaken of 310 patients with MS (early MS, disease duration ≤5 years, n = 127) and controls (n = 155), evaluating specific humoral responses to CMV, Epstein-Barr virus and human herpesvirus-6, as well as T-cell and natural killer (NK)-cell immunophenotypes.
Cytomegalovirus seroprevalence in early MS was lower than in non-early MS or controls (P < 0.01), being independently associated with disease duration (odds ratio, 1.04; 95% confidence interval, 1.01-1.08, P < 0.05). CMV+ patients with MS displayed increased proportions of differentiated T-cells (CD27-CD28-, CD57+, LILRB1+) and NKG2C+ NK-cells, which were associated with a lower disability in early MS (P < 0.05). CMV+ patients with early MS had an age-related decline in serum anti-EBNA-1 antibodies (P < 0.01), but no CMV-related differences in anti-human herpesvirus-6 humoral responses.
Low CMV seroprevalence was observed in patients with early MS. Modification of MS risk attributed to CMV might be related to the induction of differentiated T-cell and NK-cell subsets and/or modulation of Epstein-Barr virus-specific immune responses at early stages of the disease.
巨细胞病毒(CMV)感染最近与多发性硬化症(MS)易感性降低相关,尽管它是否具有保护作用还是仅仅与西方化和生命早期病毒感染有关的一种偶然现象仍存在争议。我们旨在评估 CMV 血清阳性状态在早期 MS 患者中是否与非早期 MS 患者不同,分析该病毒与 MS 临床病程以及针对其他疱疹病毒的体液免疫反应之间的潜在关联。
对 310 例 MS 患者(早期 MS,病程≤5 年,n=127)和对照组(n=155)进行了多中心分析,评估了针对 CMV、Epstein-Barr 病毒和人类疱疹病毒-6 的特异性体液反应,以及 T 细胞和自然杀伤(NK)细胞免疫表型。
早期 MS 患者的 CMV 血清阳性率低于非早期 MS 患者或对照组(P<0.01),且与疾病持续时间独立相关(优势比,1.04;95%置信区间,1.01-1.08,P<0.05)。MS 伴 CMV+患者的分化 T 细胞(CD27-CD28-、CD57+、LILRB1+)和 NKG2C+ NK 细胞比例增加,这与早期 MS 患者的残疾程度降低相关(P<0.05)。早期 MS 伴 CMV+患者的血清抗-EBNA-1 抗体随年龄增长而下降(P<0.01),但针对人类疱疹病毒-6 的体液免疫反应无 CMV 相关差异。
早期 MS 患者的 CMV 血清阳性率较低。归因于 CMV 的 MS 风险的改变可能与疾病早期诱导分化的 T 细胞和 NK 细胞亚群以及/或调节 EBV 特异性免疫反应有关。